EA200400534A1 - Стимуляция тимозином генетической иммунизации - Google Patents

Стимуляция тимозином генетической иммунизации

Info

Publication number
EA200400534A1
EA200400534A1 EA200400534A EA200400534A EA200400534A1 EA 200400534 A1 EA200400534 A1 EA 200400534A1 EA 200400534 A EA200400534 A EA 200400534A EA 200400534 A EA200400534 A EA 200400534A EA 200400534 A1 EA200400534 A1 EA 200400534A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
virus
thymosi
stimulation
genetic immunization
Prior art date
Application number
EA200400534A
Other languages
English (en)
Other versions
EA006743B1 (ru
Inventor
Джек Р. Уандс
Original Assignee
Роуд Айлэнд Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Роуд Айлэнд Хоспитал filed Critical Роуд Айлэнд Хоспитал
Publication of EA200400534A1 publication Critical patent/EA200400534A1/ru
Publication of EA006743B1 publication Critical patent/EA006743B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описано применение α-тимозина для стимуляции клеточных иммунных ответов на вирус гепатита C. Описаны способы иммунизации индивидуума, чувствительного к инфекции, которая вызывается вирусом гепатита C, против указанной инфекции, отличающиеся тем, что индивидууму вводят один или несколько полинуклеотидов, кодирующих один или несколько пептидов вируса гепатита C, в сочетании с одним или несколькими тимозинами. В заявке описаны также композиции для иммунизации против вируса гепатита C, которые содержат один или несколько полинуклеотидов, кодирующих один или несколько пептидов вируса гепатита C, в сочетании с одним или несколькими α-тимозинами.Отчет о международном поиске был опубликован 2003.12.04.
EA200400534A 2001-10-26 2002-10-28 Стимуляция тимозином генетической иммунизации EA006743B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33063801P 2001-10-26 2001-10-26
PCT/US2002/034535 WO2003035010A2 (en) 2001-10-26 2002-10-28 Thymosin augmentation of genetic immunization

Publications (2)

Publication Number Publication Date
EA200400534A1 true EA200400534A1 (ru) 2004-12-30
EA006743B1 EA006743B1 (ru) 2006-04-28

Family

ID=23290629

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400534A EA006743B1 (ru) 2001-10-26 2002-10-28 Стимуляция тимозином генетической иммунизации

Country Status (21)

Country Link
US (1) US20050054845A1 (ru)
EP (1) EP1448223B1 (ru)
JP (1) JP2005506997A (ru)
KR (1) KR100902197B1 (ru)
CN (1) CN1269524C (ru)
AT (1) ATE382365T1 (ru)
BR (1) BR0213554A (ru)
CA (1) CA2464795A1 (ru)
CY (1) CY1107371T1 (ru)
DE (1) DE60224435T2 (ru)
DK (1) DK1448223T3 (ru)
EA (1) EA006743B1 (ru)
ES (1) ES2299626T3 (ru)
IL (1) IL161603A0 (ru)
MX (1) MXPA04003867A (ru)
NO (1) NO20042124L (ru)
NZ (1) NZ532863A (ru)
PL (1) PL370453A1 (ru)
PT (1) PT1448223E (ru)
UA (1) UA81613C2 (ru)
WO (1) WO2003035010A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588685A1 (en) * 2004-12-06 2006-06-15 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as cancer vaccine adjuvants
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (ru) * 1991-09-13 1994-05-21 Paul B Chretien
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6288033B1 (en) * 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

Also Published As

Publication number Publication date
IL161603A0 (en) 2004-09-27
WO2003035010A3 (en) 2003-12-04
NO20042124L (no) 2004-05-24
EP1448223A4 (en) 2005-11-16
PL370453A1 (en) 2005-05-30
KR100902197B1 (ko) 2009-06-11
DE60224435T2 (de) 2009-01-02
CA2464795A1 (en) 2003-05-01
EP1448223A2 (en) 2004-08-25
UA81613C2 (ru) 2008-01-25
DE60224435D1 (de) 2008-02-14
NZ532863A (en) 2006-07-28
CN1269524C (zh) 2006-08-16
CY1107371T1 (el) 2012-12-19
KR20040089075A (ko) 2004-10-20
EA006743B1 (ru) 2006-04-28
EP1448223B1 (en) 2008-01-02
US20050054845A1 (en) 2005-03-10
PT1448223E (pt) 2008-01-23
JP2005506997A (ja) 2005-03-10
CN1604789A (zh) 2005-04-06
DK1448223T3 (da) 2008-02-18
MXPA04003867A (es) 2005-06-17
BR0213554A (pt) 2004-10-26
ES2299626T3 (es) 2008-06-01
WO2003035010A2 (en) 2003-05-01
ATE382365T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
ATE512231T1 (de) Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
DE69739385D1 (de) Verbesserte impfstoffe
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
DK1290160T3 (da) Humane Pellino-polypeptider
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
DK1301637T3 (da) DNA-vacciner, der koder for HIV accessoriske proteiner
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DE60229966D1 (de) Diabetesmodell
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
WO2005010035A3 (en) Alternate reading frame polypeptides derived from hepatitis c and methods of their use
DK1204420T3 (da) Trehaloseproducerende prokaryotiske celler som vacciner

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU